



Dixon, P., Davey Smith, G., & Hollingworth, W. (2019). The Association Between Adiposity and Inpatient Hospital Costs in the UK Biobank Cohort. *Applied Health Economics and Health Policy*, 17(3), 359-370. <https://doi.org/10.1007/s40258-018-0450-2>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1007/s40258-018-0450-2](https://doi.org/10.1007/s40258-018-0450-2)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Springer at <https://link.springer.com/article/10.1007%2Fs40258-018-0450-2> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>



The Association Between Adiposity and Inpatient Hospital Costs in the UK Biobank Cohort

Padraig Dixon^{1,2} · George Davey Smith^{1,2,3} · William Hollingworth¹

© The Author(s) 2018

Abstract

Background High adiposity is associated with higher risks for a variety of adverse health outcomes, including higher rates of age-adjusted mortality and increased morbidity. This has important implications for the management of healthcare systems, since the endocrinal, cardiometabolic and other changes associated with increased adiposity may be associated with substantial healthcare costs.

Methods We studied the association between various measures of adiposity and inpatient hospital costs through record linkage between UK Biobank and records of inpatient care in England and Wales. UK Biobank is a large prospective cohort study that aimed to recruit men and women aged between 40 and 69 from 2006 to 2010. We applied generalised linear models to cost per person year to estimate the marginal effect of adiposity, and average adjusted predicted costs of adiposity.

Results Valid cost and body mass index (BMI) data from 457,689 participants were available for inferential analysis. Some 54.4% of individuals included in the analysis sample had positive inpatient healthcare costs over the period of follow-up. Median hospital costs per person-year of follow-up were £89, compared to mean costs of £481. Mean BMI overall was 27.4 kg/m² (standard deviation 4.8). The marginal effect of a unit increase in BMI was £13.61 (99% confidence interval £12.60–£14.63) per person-year of follow up. The marginal effect of a standard deviation increase in BMI was £69.20 (99% confidence interval £64.98–£73.42). The marginal effect of becoming obese was £136.35 (99% confidence interval £124.62–£148.08). Average adjusted predicted inpatient hospital costs increased almost linearly when modelled using continuous measure of adiposity. Sensitivity analysis of different scenarios did not substantially change these conclusions, although there was some evidence of attenuation of the effects of adiposity when controlling for waist-hip ratios, and when individuals who self-reported any pre-existing conditions were excluded from analysis.

Conclusions Higher adiposity is associated with higher inpatient hospital costs. Further scrutiny using causal inferential methods is warranted to establish if further public health investments are required to manage the large healthcare costs observationally associated with overweight and obesity.

Key Points for Decision Makers

Higher body mass index is associated with a variety of adverse health outcomes, the management of which may have important resource requirements for health systems.

We studied the observational association between body mass index and inpatient hospital costs in the UK Biobank, a very large cohort of individuals mostly aged between 40 and 69 at recruitment.

A unit increase in body mass index was associated with higher inpatient hospital costs per person of £13.61, per year of follow-up.

These findings, in conjunction with evidence from causal analyses, may be used as inputs to guide the development of interventions and preventive programmes targeting (in particular) overweight and obesity.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s40258-018-0450-2>) contains supplementary material, which is available to authorized users.

✉ Padraig Dixon
padraig.dixon@bristol.ac.uk

¹ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK

² MRC Integrative Epidemiology Unit, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK

³ NIHR Biomedical Research Centre, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK

1 Introduction

Body mass index (BMI)—weight divided by the square of standing height—is a widely used indicator of nutritional status, adiposity and overall health [1–7]. Longitudinal, cross-country data reveal a recent increase in mean BMI levels for men and women, and increased variance in BMI [6]. Globally, more individuals are becoming obese ($\text{BMI} \geq 30 \text{ kg/m}^2$) than are transitioning out of underweight status ($\text{BMI} \leq 18.5 \text{ kg/m}^2$) [6, 8], leading to marked increases in the absolute numbers of individuals in the former category. Some 2.1 billion individuals throughout the world were overweight ($\text{BMI} > 25 \text{ kg/m}^2$) or obese in 2013, an increase of 1.4 billion from 1980 [4]. This reflects a global prevalence of overweight or obesity amongst men of 28.8% and 29.8% amongst women [4].

The underlying aetiology between BMI and health is complex [9], but robust associations have nevertheless been found between higher BMI and risks for a variety of adverse health and social outcomes, including higher rates of age-adjusted mortality [10], increased morbidity [6, 11] and poor labour market outcomes [12]. This has important implications for the management of healthcare systems [13], since the endocrinal [14], cardiometabolic [15, 16] and other changes [13] associated with increased adiposity are associated with substantial healthcare resource requirements [17].

Cawley et al. [18] estimate that the direct medical care costs of obesity of US adults amounted to 27.5% of health expenditures for non-institutionalised US adults, and noted adult obesity has become more expensive over time in the USA due to both increased prevalence and higher treatment costs. Kent et al. [19] attribute 14.6% of total annual hospital costs in women aged 55–79 in England to overweight and obesity, with this figure rising to 52% for individuals with $\text{BMI} > 40 \text{ kg/m}^2$.

This article assesses the observational association between BMI and other measures of adiposity with admitted patient hospital costs using individual-level data from UK Biobank, a large prospective cohort study. This is the first study to develop cost estimates for UK Biobank, which will be returned to the cohort and freely available for other researchers to use. Observational analyses of the type deployed in this paper cannot answer causal questions, or identify the mechanisms that mediate the association between adiposity and healthcare costs, but do have utility in documenting policy-relevant associations, offering context for previous observational and causal studies, and providing evidence for meta-analysis.

A further advantage of this analysis is that the results may be triangulated [20] with other sources of evidence with potentially orthogonal sources of bias to come to an overall view about the association between BMI and healthcare costs. Together, diverse sources of evidence, of which the present analysis is one source, can be used to inform the cost-effectiveness of interventions and policies targeting the

prevention and treatment of obesity. As Wang et al. [13] note, “A systematic understanding of the potential morbidity and cost implications of specified hypothetical changes in body-mass index trajectories...is crucial for formation of effective and cost-effective strategies, establishment of research and funding priorities, and creation of the political will to address the obesity epidemic.”

2 Methods

2.1 UK Biobank—Features of Study Design and Participants

Adults aged between 40–69 and living within approximately 25 miles (40 km) of 22 assessment centres in England, Wales and Scotland were invited to participate in the UK Biobank study. Some 9.24 million individuals registered with the UK’s National Health Service (NHS) were sent postal invitations, and 503,317 individuals ultimately joined the study cohort [21], for a response rate of approximately 5.45%. Participation rates were higher for women (6.4%) than men (5.1%) [21]. The cohort is not representative of the national population from which it is drawn, being wealthier, healthier and better educated. The implications of the response rate and the representativeness of the cohort are considered in the Discussion section below. Ethical approval for UK Biobank was received from the North West—Haydock Research Ethics Committee (reference 11/NW/0382).

Participant assessments, undertaken at the 22 centres between 2006 and 2010, comprised consent, self-completion of an electronic questionnaire, computer-assisted interviews, specimen collection and measurement of physical function [22]. Individual participant baseline data were linked with participant consent to, among other things, death registers and records of certain forms of care in NHS hospitals.

2.2 Measurement of Body Mass, Waist-Hip Ratios and Bio-impedance

Three different but cognate measures that indicate adiposity were measured at the baseline appointment: BMI measured using height and weight, bio-impedance (opposition in biological tissues to alternating current) and circumferences of the waist and hip.

Weight was measured following the removal of shoes and heavy outer clothing using Tanita BC-148MA body composition analysers. Participants’ height, standing shoeless, was measured using a Seca 202 device. These measurements were used to create an index of body mass in terms of kg/m^2 .

The built-in algorithms of the Tanita analysers were also used to estimate body composition following measurement of bio-impedance. Mass measured using impedance was

calculated in increments of 0.1 kg. A separate measure of adiposity was calculated from these impedance measures by dividing by the standing height of participants to create another index of body mass, also in terms of kg/m^2 .

These two measures of adiposity were highly concordant (Lin's $\rho = 0.99996$, $p < 0.00001$) with a mean difference between traditional and impedance measures of -0.01 (99% confidence interval -0.12 to 0.10). Impedance-based BMI was therefore used where the traditional BMI measure was missing. A total of 685 observations had a mean difference between traditional and impedance-based measures of BMI of more than 5 standard deviations from the mean difference, and were excluded from the analysis.

Waist circumference (at the umbilicus) and hip circumference were measured in centimetres using a Wessex sprung tape measure. A waist-hip ratio (WHR) was calculated from these measurements to reflect central adiposity [23, 24]. We estimated separate models including WHR as a continuous variable and as a binary variable. The binary variable was constructed to reflect measures of regional adiposity using a ratio > 0.85 for women and > 0.9 for men. It is important to note that while these binary cut-off points are used in a number of countries, there is no widely accepted definition of these cut-offs, despite the frequent attribution of these figures to WHO reports (see [25] and particularly the discussion in [26]). Nevertheless, this classification has utility as a comparison to the binary cut-off of obesity defined for the conventional BMI measures, as well to published literature using these or similar classifications for WHR measures.

As a sensitivity analysis, we estimated models of the continuous WHR outcome using continuous BMI as a covariate, and vice versa. These models estimated, respectively, BMI-adjusted WHR, and WHR-adjusted BMI outcomes conditional on all baseline covariates, and each model assumes that WHR is not on the causal pathway between BMI and hospital costs and vice versa.

2.3 Measurement of Costs

Admitted patient care episodes, sometimes referred to as inpatient care episodes, were obtained from linked Hospital Episode Statistics (HES) for English care providers and from Patient Episode Database for Wales (PEDW) for Welsh providers. These two data sources are very similar in structure and purpose, and were analysed as a single dataset following reconciliation where required. Inpatients are those who are admitted to hospital and occupy a hospital bed but need not necessarily stay overnight (i.e. day case care).

Episodes of care refer to a period of care in which a patient is under the care of a single consultant working at a single hospital provider. An admission may comprise just one "Finished Consultant Episode" (FCE), or many such

episodes if the patient receives care from more than one consultant.

Each FCE is associated with information on the patient, and the consultant and hospital overseeing their care. For example, FCEs are associated with procedures undertaken (based on OPCS-4 procedure codes) and diagnoses made (based on ICD-10 diagnosis codes [27]). These FCEs were converted into Healthcare Resource Groups (HRGs) by using data on patient characteristics, length of stay, procedures, diagnoses, and other information by using NHS "Grouper" software [28].

HRGs reflect groups of similar patient activity, and are used in England and Wales as the basis for case-mix-adjusted remuneration of publicly funded NHS hospitals. In turn, these HRGs were cross-classified against NHS Reference unit costs, allowing costs to be assigned to each FCE. These costs were calculated to reflect differences between categories of care included in inpatient care, such as elective and non-elective episodes, and accounted for the additional costs associated with patients undergoing long hospital stays. Costs were separately calculated for so-called "unbundled" elements of care, such as diagnostic imaging, for which elements of cost and care activity are represented separately from other elements of inpatient care.

Due to differences in the collection and valuation of care in Scottish hospitals compared to hospitals in England and Wales, only costs from the latter two jurisdictions are included in this analysis. Costs were calculated for episodes of care occurring on or after 1 April 2006 to reflect major changes to the hospital payment system that came into effect on that date [29]. Participants who attended UK Biobank baseline appointments before this date were removed from the analysis.

Remaining cohort members therefore report person-years from recruitment, and contribute data to HES until death, emigration, or 31 March 2015, the current censoring date for linked HES data. Note that the event of death does not constitute censoring in this analysis, since the number of all-care episodes and associated costs is known following death. Emigration out of the UK amongst the cohort is reported to be a modest 0.3% [21] and is not accounted for in our analysis. We do not have information on patients who may have received inpatient care in Scottish hospitals while living in England or Wales. Costs were converted into a per-patient cost by summing across all episode costs per person-year of follow-up in constant 2016/17 prices.

2.4 Covariates

All models adjusted for covariates obtained from participant responses at the baseline appointment at UK Biobank assessment centres. These covariates were sex, age at recruitment,

days per week of vigorous physical activity (categorical ranging from 0–7), frequency of alcohol intake (categorical ranging from “daily or almost daily” to “never”), educational and professional qualifications (categorical), employment status (categorical, ranging from “in paid employment or self-employed” to “full or part-time student”), and a measure of deprivation calculated using the Townsend score converted into quintiles.

To assess the effects of residual confounding and of reverse causality from pre-diagnostic or prodromal disease [7], we conducted sensitivity analysis restricting the analysis to include only “never smokers” ($n = 249,423$) and including only individuals reporting no pre-existing illness at baseline ($n = 106,388$). Smoking status is self-reported and may exhibit measurement error as a consequence [30]. It is possible that focusing only on never smokers (who are probably less likely to misreport their smoking status than current or former status) may avoid some of the confounding that may otherwise be present in the BMI-hospital cost association. However, the causal relationship between BMI, smoking and healthcare costs is complicated and very likely bidirectional [31, 32]. It is important to emphasise that accounting for residual confounding and reverse causality in this way is necessarily incomplete given the observational study design.

Including only those individuals with no health conditions at baseline may partially capture the impact of reverse causality if individuals with many pre-existing conditions are on treatment regimens that raise or lower BMI, so that the direction of causality runs from costs to BMI. Again, this is a partial attempt at accounting for reverse causality and reflects only baseline information that was accurately self-reported.

Two covariates (the exercise variable and the qualifications variable) had slightly higher rates of missing data than others, and we conducted a post hoc sensitivity analysis excluding these two variables from the adjusted regression models.

2.5 Statistical Methods

The primary objective of our analysis was to predict total admitted patient hospital costs as a function of the conditional marginal effect of body mass on healthcare costs. Marginal effects for categorical and binary adiposity-related variables refer to the effects of a change in category, e.g. from “overweight” to “obese”. Marginal effects for continuous outcomes were calculated for specific changes—unit changes and standard deviation changes—in the adiposity-related variable. The magnitude of these effects depends on the values of other covariates included in the model—these values of other covariates were left at their observed values to calculate an average marginal effect.

The average adjusted predictions that follow from this calculation adjust for variation in these other covariates. These predicted costs therefore do not necessarily reflect the hypothetical costs of an “average” individual, nor necessarily the expected costs for any specific individual in the sample. Average adjusted predicted costs were calculated for the entire analysis sample, for the samples defined in sensitivity analyses, and at representative ages stratified by sex.

Cost is always non-negative, the modal value is often zero, and the distribution of healthcare costs tends to be skewed with a long right tail reflecting very high expenditures incurred by a small number of individuals. Linear models may predict negative costs for some individuals, may not estimate mean effects without bias in the presence of long tails, and are likely to be inefficient in the presence of heteroskedasticity. Logarithmic transformations can address skewness to some extent but are not well suited for handling zero cost observations, and require transformations of regression output back to the original scale, a process which itself may cause bias in the presence of heteroskedasticity [33].

Generalised linear models (GLM) were therefore used to estimate average adjusted predicted costs: rather than modelling the conditional expectation of the logarithm of cost, the logarithm of the conditional expectation of cost was estimated, and the relationship of the mean to variance in the outcome data was assessed and modelled. A so called “single-index model” was used, in which the zero-cost and positive-cost outcomes were modelled with a single density function. As Deb et al. [34], this approach is appropriate when the object of inferential interest is related to the mean function of the outcome, conditional on covariates, such as the marginal effect of an adiposity-related covariate on inpatient hospital cost outcomes. However, in sensitivity analyses, we also estimated models under a two-part model which decomposed the density of the outcome into a mixture of two parts: one that models the zero cost observations (estimated with a logit model), and one that models the non-zero cost observations using a GLM structure.

Two tests, neither necessarily definitive, were used to identify an appropriate link function for all models. Box-Cox tests on positive cost observations were used to identify scalar powers that resulted in the most symmetric transformed distribution. A Pregibon-type [35] link test was performed to check whether including the squared outcome variable as a covariate had explanatory value above models excluding this term. To inform the choice of the family function, a modified version of the Park test was used to characterise the relationship between the variance of the error term and the expected value of the cost outcome variable. All models use robust standard errors to allow for potential mis-specification of the link and family functions.

All analyses were conducted in Stata version 15.1 (Stata-Corp, College Station, Texas).

3 Results

Following exclusion of data as described above, records from up to 457,689 participants were available for the inferential analysis (Fig. 1), of whom 54.4% at baseline were female (Table 1). Person-years of follow-up ranged from 4.5 to 9 years (mean and median = 6.1 years). Mean age at baseline for women was 56.3 years, and 56.7 years for men. Median hospital costs per person-year of follow-up were £89, compared to mean costs of £481, reflecting the highly skewed distribution that is characteristic of this type of cost data.

Some 54.4% of individuals included in the analysis sample had positive healthcare costs over the period of follow-up. Mean BMI overall was 27.4 kg/m² [standard deviation (SD) 4.8]; BMI amongst men was 27.8 kg/m² (SD 4.2) and amongst women 27.1 kg/m² (SD 5.2). The proportion of participants with BMI > 30 kg/m² was 24.4%, with more men (25.3%) than women (23.5%) meeting the definition of obesity. This is slightly lower than the

prevalence of obesity in England in 2010 (the last year of recruitment to the study) amongst all adults of 26.1% (26.2% males, 26.1% females) [36].

There was limited missingness (<0.1%) amongst baseline covariates used in the adjusted analysis, with the exception of the exercise variable (5.4% coded as missing) and the qualifications variable (1.9% missing). Tests of family and link functions for the GLM supported the use of a Gamma family with logarithmic link when modelling the cost outcome. Further details on the results of these tests are provided in supplementary material.

All models found a positive association between measures of adiposity and hospital costs (Table 2). Marginal effects represent a specific change in the outcome associated with each scenario, leaving other variables at their observed levels, and averaged over all individuals in the sample. For example, an increase in categorical BMI from the base category of 25 kg/m² to 27.5 kg/m² to the 30 kg/m² to 35 kg/m² category is associated with an increase in costs of £106.24 [99% confidence interval (CI) £91.59–£120.90]. This marginal effect can be interpreted as the hypothetical difference if all individuals differed only in their BMI category, but not on any other covariate. Average adjusted predictions reflect the expected values of the inpatient




Fig. 1 Flow chart of participants available for analysis. *BMI* body mass index. Ungrouped cost data refers to data for which Hospital Episode Statistics data are not sufficient to assign a Healthcare

Resource Group. This is typically where the primary diagnosis was not specific and was coded to an unspecified injury (or similar) classification

Table 1 Descriptive statistics for analysis sample

	Analysis sample	BMI 10.0 to <18.5	BMI 18.5 to <20	BMI 20 to <22.5	BMI 22.5 to <25	BMI 25 to <27.5	BMI 27.5 to <30	BMI 30 to <35	BMI 35 to <40	BMI ≥40
BMI, N =	457,689	2376	8367	46,303	94,502	109,714	84,917	80,066	22,717	8727
BMI mean (SD) (kg/m ²)	27.42 (4.78)	17.65 (0.81)	19.40 (0.42)	21.48 (0.69)	23.84 (0.71)	26.23 (0.71)	28.67 (0.71)	32.00 (1.39)	36.97 (1.38)	43.76 (3.73)
WHR, N =	457,556	2376	8364	46,292	94,488	109,689	84,902	80,033	22,703	8709
WHR mean (SD)	0.87 (0.09)	0.77 (0.06)	0.78 (0.06)	0.80 (0.07)	0.83 (0.07)	0.87 (0.08)	0.90 (0.08)	0.92 (0.09)	0.93 (0.09)	0.92 (0.10)
Sex, N =	457,689	2376	8367	46,303	94,502	109,714	84,917	80,066	22,717	8727
Female (%)	54.38	79.21	79.67	72.92	59.86	48.74	44.67	48.78	59.69	68.40
Male (%)	45.62	20.79	20.33	27.08	40.14	51.26	55.33	51.22	40.31	31.60
Days exercise, N =	433,259	2239	7941	44,518	90,627	104,607	80,151	74,488	20,787	7901
0 (%)	37.17	44.08	36.85	32.39	31.81	34.22	37.82	43.56	51.29	59.38
1 (%)	14.14	13.93	14.80	15.31	15.04	14.69	13.86	12.91	11.70	10.40
2 (%)	15.85	12.77	15.00	16.42	17.07	16.76	15.61	14.62	12.78	10.77
3 (%)	13.81	9.96	12.66	14.94	15.35	14.56	13.64	12.12	10.44	8.72
4 (%)	6.51	4.87	6.80	7.23	7.39	6.91	6.52	5.43	4.32	3.28
5 (%)	6.89	6.97	6.51	7.10	7.19	7.20	7.07	6.47	5.50	4.28
6 (%)	2.00	1.65	2.35	2.38	2.19	2.13	1.91	1.72	1.36	1.14
7 (%)	3.61	5.76	5.04	4.23	3.95	3.52	3.59	3.17	2.61	2.03
Alcohol frequency N =	456,669	2363	8335	46,205	94,344	109,485	84,746	79,848	22,643	8700
Daily or almost daily (%)	20.55	22.09	22.66	22.75	22.84	22.28	20.82	17.45	12.08	7.56
Three or four times a week (%)	23.07	18.74	21.82	24.29	24.81	24.81	23.71	20.78	15.97	11.41
Once or twice a week (%)	25.71	18.91	21.99	24.34	25.72	25.83	26.34	26.49	25.81	22.98
One to three times a month (%)	11.13	9.60	10.53	10.55	10.26	10.33	10.63	12.51	15.10	16.67
Special occasions (%)	11.54	15.32	12.42	10.39	9.57	9.89	10.81	13.68	19.30	25.10
Never (%)	8.01	15.32	10.57	7.68	6.80	6.86	7.70	9.09	11.74	16.28
Qualifications, N =	448,825	2311	8215	45,554	92,831	107,669	83,240	78,294	22,175	8536

Table 1 (continued)

Analysis sample	BMI 10.0 to <18.5	BMI 18.5 to <20	BMI 20 to <22.5	BMI 22.5 to <25	BMI 25 to <27.5	BMI 27.5 to <30	BMI 30 to <35	BMI 35 to <40	BMI ≥40	
College/university degree (%)	32.31	41.32	43.29	42.01	37.66	32.99	28.90	25.32	23.13	21.88
A levels or equivalent (%)	11.21	13.24	13.33	12.92	11.75	11.17	10.73	10.21	10.30	10.65
O levels or equivalent (%)	21.81	19.26	19.81	20.26	21.63	22.04	21.94	22.28	22.97	23.28
CSEs or equivalent (%)	5.80	3.76	4.67	4.93	5.20	5.48	6.14	6.69	6.84	8.32
NVQ or equivalent (%)	6.66	3.94	3.60	4.15	5.46	6.77	7.80	8.07	8.02	8.07
Other professional qualifications (%)	5.21	4.24	4.25	4.68	4.84	5.17	5.46	5.72	5.64	5.37
None of the above (%)	16.99	14.24	11.05	11.04	13.47	16.37	19.03	21.72	23.11	22.43
Employment, N=	455,287	2357	8313	46,074	94,073	109,168	84,475	79,587	22,568	8672
In paid employment/self-employed (%)	57.67	52.14	59.34	61.32	59.68	57.74	56.63	55.65	54.17	52.43
Retired (%)	33.38	29.24	27.19	28.52	32.51	34.97	35.40	34.29	32.91	29.13
Looking after home/family (%)	2.80	6.50	6.09	4.61	3.12	2.27	2.09	2.29	2.78	3.54
Unable to work because of ill health (%)	3.17	6.67	3.39	2.33	1.93	2.23	2.99	4.59	6.82	11.05
Unemployed (%)	1.69	3.31	2.11	1.52	1.40	1.54	1.76	1.93	2.24	2.69
Doing unpaid work (%)	0.47	1.06	0.73	0.70	0.53	0.43	0.36	0.40	0.34	0.51
Full or part time student (%)	0.26	0.34	0.45	0.36	0.27	0.25	0.24	0.23	0.23	0.24
None of the above (%)	0.57	0.64	0.71	0.64	0.57	0.56	0.54	0.62	0.50	0.42

Table 1 (continued)

	Analysis sample	BMI 10.0 to <18.5	BMI 18.5 to <20	BMI 20 to <22.5	BMI 22.5 to <25	BMI 25 to <27.5	BMI 27.5 to <30	BMI 30 to <35	BMI 35 to <40	BMI ≥40
Quintile of deprivation, N=	457,156	2371	8358	46,251	94,386	109,606	84,815	79,968	22,689	8712
1 (lowest deprivation) (%)	20.06	17.63	18.95	20.95	21.90	21.56	20.03	17.98	14.59	11.81
2 (%)	20.00	17.17	18.09	19.92	21.21	20.69	20.51	18.92	16.93	13.88
3 (%)	20.0	16.91	19.19	20.06	20.16	20.58	20.24	19.67	18.37	17.57
4 (%)	20.01	21.00	20.81	20.12	19.41	19.58	19.89	20.51	21.80	21.91
5 (highest deprivation) (%)	19.93	27.29	22.96	18.95	17.32	17.59	19.33	22.91	28.31	34.83
Age at recruitment, N=	457,689	2376	8367	46,303	94,502	109,714	84,917	80,066	22,717	8727
Age (years) at recruitment mean (SD)	56.52 (8.10)	55.40 (8.15)	54.53 (8.3)	54.98 (8.27)	56.14 (8.17)	56.89 (8.08)	57.13 (8.03)	57.05 (7.91)	56.58 (7.82)	55.44 (7.71)

BMI body mass index, CSE Certificate of Secondary Education, NVQ National Vocational Qualification, SD standard deviation, WHR waist hip ratio

cost outcome for specific sets of values for the predictor variables, for example, the effect of a standard deviation increase in BMI.

Marginal effects for continuous outcomes require the specification of a particular “margin” of change, but otherwise have a similar interpretation of the marginal effects of categorical outcomes. For example, the effect of a one standard deviation increase in BMI is to increase in inpatient hospital costs by £69.20 (99% CI £64.98–£73.42).

The relative effect of a unit change in continuous BMI amounts to approximately 2.9% (99% CI 2.7–3.2) in increased costs per person-year of follow-up.

Figure 2 displays average adjusted predicted costs at representative values of continuous BMI, capturing predictions at unit increments of BMI from small to the large BMI values. Figure 3 presents the same outcome according to age, and stratified by sex to examine whether these variables may influence inpatient costs. The point estimates and CIs are similar, and no difference in sex is apparent at any age. However, there is a clear gradient with respect to age, with older members of the cohort predicted to have higher inpatient costs. Figure 4 summarises average marginal effects for the categorical BMI outcome. There is some evidence of a J-shaped relationship in point estimates for lower levels of categorical BMI, although this evidence is weak given the widths of the CIs around these estimates.

Three of the five specifications assessed in sensitivity analysis were very similar to the base-case predictions (Fig. 5). The effect of BMI attenuates slightly when controlling for WHR. Including only never-smokers slightly reduced the estimated marginal effect to £13.10 (99% CI £11.77–£14.43), and predicted costs are similar to the base model near mean BMI. Excluding individuals who reported no pre-existing health conditions had the largest impact of all scenarios assessed, reducing the marginal effect of a unit change of BMI to £5.51 (99% CI £4.13–£6.89). Supplementary material describes average adjusted predictions over the range of BMI for these sensitivity analyses. Results from sensitivity analyses of the other outcomes reported in Table 2 were similar.

4 Discussion

Higher rates of adiposity are associated with higher inpatient hospital costs in this cohort of middle-aged and older individuals. This is broadly consistent with findings from studies with similar designs. A systematic review [37] of the association between total annual healthcare costs and BMI in studies using individual participant data found progressive increases in annual hospital costs for increasing levels of obesity, a finding demonstrated here in all

models and for all outcomes. The systematic review also reported that overweight and obesity increased median inpatient hospital costs relative to costs associated with BMI of 18.5 kg/m² to <25 kg/m² by 12% and 34%, respectively. These figures are similar to those reported here, for which the comparable relative increases in cost for BMI 25 kg/m² to <27.5 kg/m² relative to 22.5 to 25 kg/m² of 16%, and 31% for BMI ≥ 30 kg/m² relative to 22.5 to <25 kg/m².

Korda et al. [38] studied hospital costs amongst 224,254 Australian adults aged at least 45 years, and found an increase in costs of between 14 and 24% (depending on category of age) for BMI between 27.5–30 kg/m² relative to 22.5–<25 kg/m², rising to 77% to 115% for BMI between 40–50 kg/m². The comparable increase in costs for individuals of all ages in UK Biobank ≥ 40 kg/m² is 78%. The findings are also broadly similar to the US study of Andreyeva et al. [39].

Marginal effects for the continuous BMI outcome are similar to the observational estimates in Cawley et al. [18] for US adults of \$49 in 2005 US dollars per unit change in BMI, although their estimate of the marginal effect of obesity (\$656) is much higher than the effect reported in Table 2 for the UK Biobank cohort. Predicted costs and marginal effects are estimated to be somewhat lower than in the large prospective women-only study of Kent et al. [19], perhaps

reflecting the relatively “healthier and wealthier” composition of participants in UK Biobank.

4.1 Strengths and Limitations

This analysis benefitted from access to a large volume of patient level data obtained from a prospective cohort study with comprehensive information on a variety of baseline




Fig. 2 Average adjusted predicted healthcare costs by continuous body mass index (BMI)

Table 2 Marginal effects and average adjusted predicted inpatient hospital costs

	Marginal effect	99% confidence interval	Average adjusted predicted cost	99% confidence interval
Outcome: continuous BMI				
Effect of unit change in BMI	£13.61	£12.60 to £14.63	£468.30	£464.84 to £471.77
Effect of SD change in BMI	£69.20	£64.98 to £73.42	£537.51	£531.69 to £543.32
Outcome: binary BMI				
Effect of change in BMI-defined obesity status	£136.35	£124.62 to £148.08	£569.25	£561.51 to £576.99
Outcome: categorical BMI				
10 to <18.5 kg/m ²	£41.62	–£77.86 to £161.10	£473.35	£354.31 to £592.39
18.5 to <20 kg/m ²	–£31.94	–£68.91 to £ 5.03	£399.79	£364.04 to £435.55
20 to <22.5 kg/m ²	–£40.94	–£57.02 to –£24.86	£390.79	£377.44 to £404.15
22.5 to <25 kg/m ²	–£20.83	–£34.52 to –£7.15	£410.90	£400.65 to £421.15
25 to <27.5 kg/m ² (base category)	–	–	£431.73	£422.91 to £440.56
27.5 to <30 kg/m ²	£46.01	£31.39 to £60.63	£477.74	£466.05 to £489.43
30 to <35 kg/m ²	£106.24	£91.59 to £120.90	£537.98	£526.52 to £549.44
35 to <40 kg/m ²	£188.99	£162.37 to £215.61	£620.72	£595.83 to £645.62
≥ 40 kg/m ²	£300.14	£257.60 to £342.69	£731.87	£690.43 to £773.32
Outcome: continuous WHR				
Effect of 0.01 change in WHR	£8.79	£8.20 to £9.38	£476.51	£472.91 to £480.12
Effect of SD change in WHR	£85.06	£78.93 to £91.18	£552.77	£545.25 to £560.30
Outcome: binary WHR				
Effect of change in regional adiposity status	£96.78	£85.78 to £105.87	£514.16	£508.50 to £519.82

BMI body mass index, SD standard deviation, WHR waist hip ratio

characteristics. Measures of BMI and related variables were obtained by research staff, and the errors and biases associated with self-report of weight and height were avoided [40]. The use of traditional and impedance-based measures of BMI offered a degree of further validation for the core exposure. The analysis included both continuous and categorical/binary outcomes of weight-related measures, in contrast to much of the literature on these associations, which is generally restricted to categorical or binary classifications of BMI.

The analysis has a number of limitations. The analysis presented in this paper is observational and cannot reveal the causal association between measures of adiposity and inpatient costs. For example, the association between costs and BMI may be confounded by the effect of unmeasured baseline health conditions that affect both BMI and hospital costs. Adjustment for baseline pre-existing conditions in sensitivity analysis revealed a relatively large moderating effect, but only captures known health conditions that were accurately reported at baseline.

The results could therefore be affected by some degree of reverse causality, the precise degree of which cannot be uncovered in this type of observational analysis. The results from excluding individuals without pre-existing conditions was suggestive—effect sizes attenuated but did not encompass the null. Nevertheless, this is necessarily a partial and incomplete test of reverse causality.

A further channel for costs to influence BMI may be treatment regimens that affect weight (such as selective serotonin reuptake inhibitors for depression), or treatment decisions that used BMI thresholds (such as for bariatric surgery) as a basis for intervention. However, observing these associations may give the appearance of the direction of causality running from healthcare costs to BMI, but in reality, are better conceived of as further instances of confounding (by depression in the first example) rather




Fig. 3 Average adjusted predicted healthcare costs stratified by age and sex




Fig. 4 Summarises average marginal effects for the categorical BMI outcome

than an actual causal effect on the level of BMI from the level of costs per se.

Methods for causal inference, such as Mendelian Randomization—the use of germline genetic variants as instrument variables for exposures such as BMI—or the use of BMI of a biological relative as an instrument for own BMI, offer promise in this area as a means to overcome confounding [41]. Complementary study designs and triangulation [20] between these different designs will almost certainly be necessary even after causal analyses of the adiposity/cost relationship.

Biobank cohort participants differ from the general population: they are more likely to be older, female and university graduates. They are less likely to be deprived, obese, to smoke, to drink alcohol on a daily-basis, or to have self-reported health conditions. There is evidence of a selection bias from a “healthy volunteer” effect [21]. The rate of all-cause mortality is 46% lower in the cohort than in the




Fig. 5 Average marginal effects per unit change in continuous body mass index (BMI)

population from which it was drawn [22]. This may induce associations between outcomes and participant characteristics when none exist in truth due to the operation of collider bias caused by the self-selection of a healthier and more educated population into the cohort [42].

This is likely to impair the representativeness and generalisability of the findings of this study to the wider UK population from which the cohort is drawn. The direction of the bias that this imparts is unknown. However, it is plausible that the direction of bias may be downwards, suggesting that the estimates presented here are likely to be an underestimate of the effect of BMI on healthcare costs. This would occur if, for example, the healthy behaviours and favourable circumstances of cohort participants (relative to the general population) are related to unmeasured variables that themselves tend to mitigate the consequences of higher BMI. Robust causal methods are required to resolve this uncertainty.

Modelling cost outcomes is challenging, not least because methods to identify appropriate link and family functions in GLM have limitations and require a degree of contextual interpretation. Mis-specification is possible despite robust standard errors being used for all models. The costs assigned to each individual episode of care are based on HRGs that are essentially averages of costs of types of care, and may conceal individual variation in actual resources used.

Analysis did not encompass all healthcare costs. Primary care data are not linked to UK Biobank, and hospital data are restricted to inpatient care, although Kent et al. [19] report that 30–50% of total overweight and obesity attributable costs relate to inpatient care. It is also probable that many costs will be correlated with the same direction of effect across different categories of provider care, albeit that the scale of effects is likely to differ. This question requires linked data that are not available for the UK Biobank cohort. The remuneration of Scottish hospitals differs from that in England and Wales, and Scottish hospitalisation data could not be combined with those from the latter two jurisdictions.

The dataset includes private patients treated in NHS hospitals, but not private patients treated elsewhere. Approximately 37% of the cohort answered a question on use of private health insurance, of whom 2.4% self-report exclusive use of private healthcare. Nevertheless, 39% of individuals reporting exclusive use of private healthcare have non-zero NHS inpatient costs. Further data on reported use of private healthcare in the cohort are presented in Supplementary material.

5 Conclusion

BMI is a potentially modifiable risk factor for a variety of healthcare conditions. Evidence from analysis of the UK Biobank is consistent with findings from other cohorts in

demonstrating a robust association between BMI and inpatient hospital costs. However, evidence from randomised study designs and/or valid causal inference on observational data is required to validate these findings and to inform public policy toward excess adiposity.

Data Availability Statement The terms of access to UK Biobank do not permit data sharing by third parties. However, data used in this study are available via application to UK Biobank. Code used in the analysis is available from: github.com/pdixon-econ.

Acknowledgements This research has been conducted using the UK Biobank Resource under Application number 29294.

Compliance with Ethical Standards

Funding statement PD and GDS are members of the MRC Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council and the University of Bristol (MC_UU_12013/1, MC_UU_12013/9). PD acknowledges support from a Medical Research Council Skills Development Fellowship (MR/P014259/1).

Conflict of interest PD, GDS and WH declare no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

References

1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet*. 2011;377(9765):557–67.
2. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. *Lancet*. 2009;373(9669):1083–96.
3. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013;309(1):71–82.
4. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014;384(9945):766–81.
5. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al. The global obesity pandemic: shaped by global drivers and local environments. *Lancet*. 2011;378(9793):804–14.
6. NCD Risk Factor Collaboration. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of

- 1698 population-based measurement studies with 19.2 million participants. *Lancet*. 2016;387(10026):1377–96.
7. Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. *Lancet*. 2016;388(10046):776–86.
 8. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet*. 2013;382(9890):427–51.
 9. Corbin LJ, Timpson NJ. Body mass index: has epidemiology started to break down causal contributions to health and disease? *Obesity*. 2016;24(8):1630–8.
 10. Wade KH, Carslake D, Sattar N, Davey Smith G, Timpson NJ. BMI and mortality in UK Biobank: revised estimates using Mendelian randomization. *Obesity*. 2018;26:1796–806.
 11. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation (WHO Technical Report Series 894). Geneva; 2000.
 12. Cawley J. An economy of scales: a selective review of obesity's economic causes, consequences, and solutions. *J Health Econ*. 2015;43:244–68.
 13. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. *Lancet*. 2011;378(9793):815–25.
 14. Corbin LJ, Richmond RC, Wade KH, Burgess S, Bowden J, Smith GD, et al. Body mass index as a modifiable risk factor for type 2 diabetes: refining and understanding causal estimates using Mendelian randomisation. *Diabetes*. 2016;65(10):3002–7.
 15. Lyall DM, Celis-Morales C, Ward J, Iliodromiti S, Anderson JJ, Gill JMR, et al. Association of body mass index with cardiometabolic disease in the UK Biobank: a Mendelian randomization study. *JAMA Cardiol*. 2017;2(8):882–9.
 16. Emdin CA, Khera AV, Natarajan P, et al. Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease. *JAMA*. 2017;317(6):626–34.
 17. Lehnert T, Sonntag D, Konnopka A, Riedel-Heller S, König HH. Economic costs of overweight and obesity. *Best Pract Res Clin Endocrinol Metab*. 2013;27(2):105–15.
 18. Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status. *Pharmacoeconomics*. 2015;33(7):707–22.
 19. Kent S, Green J, Reeves G, Beral V, Gray A, Jebb SA, et al. Hospital costs in relation to body-mass index in 1.1 million women in England: a prospective cohort study. *Lancet Public Health*. 2017;2(5):e214–22.
 20. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. *Int J Epidemiol*. 2016;45(6):1866–86.
 21. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with the general population. *Am J Epidemiol*. 2017;186(1):1026–34.
 22. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12(3):e1001779.
 23. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature*. 2015;518(7538):187–96.
 24. Vazquez G, Duval S, Jacobs JDR, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. *Epidemiol Rev*. 2007;29(1):115–28.
 25. World Health Organization. Global strategy for the prevention and control of noncommunicable diseases. Geneva: World Health Organization; 2000.
 26. World Health Organization. Waist circumference and waist-hip ratio report of a WHO expert consultation. Geneva: World Health Organization; 2008.
 27. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
 28. NHS. Reference costs grouper 2016. <http://content.digital.nhs.uk/casemix/costing>. Accessed 1 May 2018.
 29. Department of Health. A simple guide to payment by results. Leeds; 2012. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/213150/PbRSimple-Guide-FINAL.pdf. Accessed 10 Aug 2018.
 30. Lawlor DA, Hart CL, Hole DJ, Smith GD. Reverse causality and confounding and the associations of overweight and obesity with mortality. *Obesity*. 2012;14(12):2294–304.
 31. Taylor A, Richmond R, Palviainen T, Loukula A, Kaprio J, Relton C, et al. The effect of body mass index on smoking behaviour and nicotine metabolism: a Mendelian randomization study. *Hum Mol Genet*. 2018. <https://doi.org/10.1101/299834>.
 32. Carreras-Torres R, Johansson M, Haycock PC, Relton CL, Davey Smith G, Brennan P, et al. Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. *BMJ*. 2018;361:k1767. <https://doi.org/10.1101/299834>.
 33. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. *J Health Econ*. 1998;17(3):283–95.
 34. Deb P, Norton EC, Manning WG. Health econometrics using Stata. College Station: Stata Press; 2017.
 35. Pregibon D. Goodness of link tests for generalized linear models. *J R Stat Soc Ser C (Appl Stat)*. 1980;29(1):15–23.
 36. NHS Information Centre. Health survey for England, 2010. London: NHS Information Centre; 2011.
 37. Kent S, Fusco F, Gray A, Jebb Susan A, Cairns Benjamin J, Mihaylova B. Body mass index and healthcare costs: a systematic literature review of individual participant data studies. *Obes Rev*. 2017;18(8):869–79.
 38. Korda RJ, Joshy G, Paige E, Butler JRG, Jorm LR, Liu B, et al. The relationship between body mass index and hospitalisation rates, days in hospital and costs: findings from a large prospective linked data study. *PLoS ONE*. 2015;10(3):e0118599.
 39. Andreyeva T, Sturm R, Ringel Jeanne S. Moderate and severe obesity have large differences in health care costs. *Obes Res*. 2012;12(12):1936–43.
 40. Connor Gorber S, Tremblay M, Moher D, Gorber B. A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. *Obes Rev Off J Int Assoc Study Obes*. 2007;8(4):307–26.
 41. Dixon P, Davey Smith G, von Hinke S, Davies NM, Hollingworth W. Estimating marginal healthcare costs using genetic variants as instrumental variables: Mendelian randomization in economic evaluation. *Pharmacoeconomics*. 2016;34(11):1075–86.
 42. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection bias can substantially influence observed associations. *Int J Epidemiol*. 2018;47(1):226–35.